Trial Profile
S0910, A Phase II Study of Epratuzumab (NSC-716711) in Combination With Cytarabine and Clofarabine for Patients With Relapsed or Refractory Ph- Negative Precursor B-Cell Acute Lymphoblastic Leukemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Apr 2023
Price :
$35
*
At a glance
- Drugs Epratuzumab (Primary) ; Clofarabine; Cytarabine
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 03 Oct 2017 Status changed from active, no longer recruiting to completed.
- 12 Nov 2013 Planned end date changed from 1 Jul 2017 to 1 Aug 2017 as reported by ClinicalTrials.gov.
- 10 Jan 2013 Planned end date changed from 1 Dec 2012 to 1 Jul 2017 as reported by ClinicalTrials.gov.